Literature DB >> 2440859

A monoclonal antibody recognizing an icosapeptide sequence in the heavy chain of human factor XII inhibits surface-catalyzed activation.

R A Pixley, L G Stumpo, K Birkmeyer, L Silver, R W Colman.   

Abstract

A monoclonal antibody (mAb B7C9) to human factor XII was raised in murine somatic cell using purified factor XII antigen. The purified antibody was subtyped IgG1 kappa and had a KD of 9.8 nM for antigen factor XII. Functional studies indicated that mAb B7C9 blocks surface-mediated coagulant activity of factor XII but not the amidolytic activity of factor XIIa against the small substrate H-D-Pro-Phe-Arg-p-nitroanilide (S-2302), suggesting that the mAb B7C9 epitope is located at or near the surface binding domain of the heavy chain region of factor XII. Western blot analysis indicated that the antibody reacts with factor XII and the heavy chain of factor XIIa. Affinity isolation of factor XII peptides, produced after cleavage by kallikrein, resulted in three factor XII heavy chain domain segments that were identified in the known factor XII sequence by limited N-terminal analysis. The epitope was located to a 20-amino acid sequence of 2.5 kDa in the heavy chain of factor XII which is the putative surface binding region of factor XII. The 2.5-kDa peptide was synthesized and demonstrated to react with mAb B7C9. mAb B7C9 was immobilized on an affinity resin and was successfully utilized to purify functionally active factor XII from plasma.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2440859

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

1.  Factor XII inhibition reduces thrombus formation in a primate thrombosis model.

Authors:  Anton Matafonov; Philberta Y Leung; Adam E Gailani; Stephanie L Grach; Cristina Puy; Qiufang Cheng; Mao-Fu Sun; Owen J T McCarty; Erik I Tucker; Hiroaki Kataoka; Thomas Renné; James H Morrissey; Andras Gruber; David Gailani
Journal:  Blood       Date:  2014-01-09       Impact factor: 22.113

Review 2.  Factor XII: what does it contribute to our understanding of the physiology and pathophysiology of hemostasis & thrombosis.

Authors:  Evi Stavrou; Alvin H Schmaier
Journal:  Thromb Res       Date:  2010-03       Impact factor: 3.944

Review 3.  Single-chain factor XII: a new form of activated factor XII.

Authors:  Ivan Ivanov; Anton Matafonov; David Gailani
Journal:  Curr Opin Hematol       Date:  2017-09       Impact factor: 3.284

4.  Modulation of the human monocyte binding site for monomeric immunoglobulin G by activated Hageman factor.

Authors:  P Chien; R A Pixley; L G Stumpo; R W Colman; A D Schreiber
Journal:  J Clin Invest       Date:  1988-11       Impact factor: 14.808

5.  The structure of the FnI-EGF-like tandem domain of coagulation factor XII solved using SIRAS.

Authors:  D X Beringer; L M J Kroon-Batenburg
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2013-01-26

Review 6.  Contact activation of blood-plasma coagulation.

Authors:  Erwin A Vogler; Christopher A Siedlecki
Journal:  Biomaterials       Date:  2009-01-24       Impact factor: 12.479

7.  Anti-Factor XII Autoantibodies in Patients with Recurrent Pregnancy Loss Recognize the Second Epidermal Growth Factor-Like Domain.

Authors:  Yoshihiro Sato; Toshitaka Sugi; Rie Sakai
Journal:  TH Open       Date:  2019-09-03

Review 8.  Factor XII in inflammation and wound healing.

Authors:  Evi X Stavrou
Journal:  Curr Opin Hematol       Date:  2018-09       Impact factor: 3.218

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.